Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2 - Barr, Paul M.; Robak, Tadeusz; Owen, Carolyn; Tedeschi, Alessandra; Bairey, Osnat; Bartlett, Nancy L.; Burger, Jan A.; Hillmen, Peter; Coutre, Steven; Devereux, Stephen; Grosicki, Sebastian; McCarthy, Helen; et al. (Haematologica (Roma), 2018)
Keywords: Aged; Aged, 80 and over; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers, Tumor; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell - genetics; Male; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - therapeutic use; Pyrazoles - administration & dosage; Pyrazoles - adverse effects; Pyrazoles - therapeutic use; Pyrimidines - administration & dosage; Pyrimidines - adverse effects; Pyrimidines - therapeutic use; Treatment Outcome